Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 15, 2021
Reporting Period: Event date June 15, 2021; Expected closing June 18, 2021.
Context: The Company, an emerging growth company, entered into an underwriting agreement for a public offering of common stock.
Key Financial Metrics
Capital Raise Details:
- Shares Issued: 3,046,358 shares of Common Stock.
- Public Offering Price: $37.75 per share.
- Underwriters' Purchase Price: $35.485 per share.
- Option Shares: Underwriters exercised an option to purchase an additional 456,953 shares in full on June 16, 2021.
- Gross Proceeds: Approximately $132.3 million (before deducting underwriting discounts, commissions, and offering expenses).
Other Metrics: The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity ratios as this is a transaction report rather than a periodic financial statement.
Material Changes
This filing reports a material change in the Company's capital structure through the issuance of new equity. The Company raised approximately $132.3 million in gross proceeds, significantly increasing its cash position pending the closing of the transaction. No prior comparable period financial data is provided in this document to assess changes in operating metrics.
Guidance, Outlook, and Risks
Management Commentary: The offering is being made pursuant to an effective registration statement on Form S-3ASR. The transaction is subject to customary closing conditions.
Risks and Contingencies:
- The offering is subject to customary closing conditions.
- The Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions.
- Representations and warranties were made solely for the benefit of the parties to the agreement and may be subject to limitations.
Unusual Items: None reported beyond the standard terms of the underwriting agreement.
Investor Verification Checklist
- Verify the final closing date of the offering (expected June 18, 2021).
- Confirm the net proceeds after deducting underwriting discounts and offering expenses.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination rights.
- Check subsequent filings for the use of proceeds and updated cash balance.